Lifileucel TIL Cell Therapy in Combination with Pembrolizumab DemonstratesDeep, Durable Responses in Frontline Advanced Melanoma Patientsin IOV-COM-202 Clinical Study ASCO Oral Presentation to Highlight 65% Objective Response Rate (ORR) and 30% Complete Response Rate Nearly All Responses Remain Ongoing at a Median Follow-up of 21.7 Months in the Oral Presentation Data in Published Abstract and Upcoming Oral PresentationStrongly Support Ongoing TILVANCE-301 Phase 3 Trial SAN CARLOS, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc.

Lifileucel TIL细胞疗法联合Pembrolizumab在IOV-COM-202临床研究ASCO口腔介绍中证明了一线晚期黑色素瘤患者的深度，持久反应，以突出65%的客观缓解率（ORR）和30%的完全缓解率几乎所有的反应仍在进行中位随访21.7个月在已发表的摘要和即将发表的口腔介绍中的数据强烈支持正在进行的TILVANCE-301 3期临床试验加利福尼亚州圣卡洛斯，2024年5月23日（环球新闻网）--Iovance Biotherapeutics，Inc。

(NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced updated clinical data for lifileucel in combination with pembrolizumab in frontline advanced melanoma, as well as translational data, for the upcoming 2024 ASCO Annual Meeting to be held May 31 – June 4, 2024, at McCormick Place in Chicago, IL and online.

（纳斯达克股票代码：IOVA）是一家商业生物技术公司，专注于创新，开发和为癌症患者提供新型多克隆肿瘤浸润淋巴细胞（TIL）疗法，今天宣布了lifileucel联合pembrolizumab治疗前线晚期黑色素瘤的最新临床数据，以及即将于2024年5月31日至6月4日在伊利诺伊州芝加哥麦考密克广场举行的2024年ASCO年会的翻译数据。

Clinical Data in Frontline Advanced Melanoma (Cohort 1A in IOV-COM-202 Trial)Positive results from Cohort 1A in the IOV-COM-202 trial were published in an abstract1 and will be highlighted in an upcoming oral presentation at ASCO. Unprecedented response rates, as well as deep and durable responses, were observed in patients with frontline advanced melanoma who were naïve to immune checkpoint inhibitor (ICI) therapy.

一线晚期黑色素瘤的临床数据（IOV-COM-202试验中的队列1A）IOV-COM-202试验中队列1A的阳性结果发表在摘要1中，并将在ASCO即将举行的口头报告中予以强调。对于未接受免疫检查点抑制剂（ICI）治疗的一线晚期黑色素瘤患者，观察到前所未有的反应率以及深度和持久的反应。

These results strongly support the ongoing Phase 3 TILVANCE-301 clinical trial. ASCO Oral Presentation Highlights A recent data cut included 23 patients with a median follow up of 21.7 months.2 Confirmed ORR was 65.2%, including 7 (30.4%) complete responses and 8 (34.8%) partial responses by RECIST v1.1.All evaluable patients demonstrated regression of th.

这些结果强烈支持正在进行的3期TILVANCE-301临床试验。ASCO口头介绍突出显示最近的数据削减包括23名患者，中位随访时间为21.7个月[2]。RECIST v1.1证实ORR为65.2%，其中7例（30.4%）完全缓解，8例（34.8%）部分缓解。所有可评估患者均表现出th消退。